Finally, in an attempt to predict the response of HNSCC patients to selective tyrosine kinase inhibitors (TKIs) against the fibroblast growth factor receptor (FGFR) pathway, the methylation profiles of FGFR (FGF1-14, FGF16-23), FGF receptor (FGFR1-4), and cyclin D1 (CCND1) have been investigated for their potential to be used as predictive biomarkers of response to the selective FGFR1/3 inhibitors PD 173074 and AZD4547 [83]. The gene discussed is FGFR1; the disease is head and neck squamous cell carcinoma.